Pyxis Oncology (PYXS) Stock Price, News & Analysis

-0.02 (-0.48%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
257,342 shs
Average Volume
722,530 shs
Market Capitalization
$244.39 million
P/E Ratio
Dividend Yield
Price Target

Pyxis Oncology MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
112.0% Upside
$8.80 Price Target
Short Interest
3.95% of Float Sold Short
Dividend Strength
News Sentiment
0.89mentions of Pyxis Oncology in the last 14 days
Based on 10 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.97) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

520th out of 921 stocks

Pharmaceutical Preparations Industry

241st out of 429 stocks

PYXS stock logo

About Pyxis Oncology Stock (NASDAQ:PYXS)

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Stock Price History

PYXS Stock News Headlines

PYXS Oct 2024 10.000 call
3 Biotech Stocks to Buy on the Dip: March 2024
Pyxis Oncology: Q4 Earnings Insights
Pyxis Oncology (PYXS) Receives a Buy from Leerink Partners
PYXS Apr 2024 10.000 call
See More Headlines
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.13 per share


Free Float
Market Cap
$244.39 million
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. John L. Flavin M.B.A. (Age 53)
    MBA, Ph.D., Co-Founder & Independent Chairman
    Comp: $87.5k
  • Dr. Lara S. Sullivan M.D.
    MBA, CEO, President & Director
  • Ms. Pamela Yanchik Connealy M.B.A. (Age 62)
    CFO & COO
    Comp: $709.7k
  • Mr. Ken Kobayashi FACP (Age 63)
    M.D., Chief Medical Officer
    Comp: $314.08k
  • Mr. Jitendra Wadhane (Age 43)
    Chief Accounting Officer, Senior VP of Finance & Corporate Controller
  • Dr. Balu N. Balasubramanian Ph.D.
    Interim Chief Technology Officer
  • Dr. Jan Pinkas Ph.D.
    Chief Scientific Officer
  • Dr. Charles T. Gombar Ph.D.
    Senior Vice President of Portfolio & Program Management

PYXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pyxis Oncology stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PYXS shares.
View PYXS analyst ratings
or view top-rated stocks.

What is Pyxis Oncology's stock price target for 2024?

7 Wall Street analysts have issued 1 year price targets for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $12.00. On average, they predict the company's stock price to reach $8.80 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price.
View analysts price targets for PYXS
or view top-rated stocks among Wall Street analysts.

How have PYXS shares performed in 2024?

Pyxis Oncology's stock was trading at $1.80 at the beginning of 2024. Since then, PYXS stock has increased by 130.6% and is now trading at $4.15.
View the best growth stocks for 2024 here

When is Pyxis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our PYXS earnings forecast

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) released its quarterly earnings results on Saturday, May, 11th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.19. The business had revenue of $16.15 million for the quarter, compared to analysts' expectations of $4.25 million.

What ETF holds Pyxis Oncology's stock?

Tema Oncology ETF holds 16,238 shares of PYXS stock, representing 0.38% of its portfolio.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an IPO on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

Who are Pyxis Oncology's major shareholders?

Pyxis Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include StemPoint Capital LP (3.05%), Ikarian Capital LLC (2.82%), Vanguard Group Inc. (2.38%), Susquehanna Fundamental Investments LLC (0.14%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Darren S Cline, Jitendra Wadhane, Lara Sullivan, Mark Chin, Pamela Ann Connealy, Pfizer Inc and Thomas Civik.
View institutional ownership trends

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYXS) was last updated on 5/17/2024 by Staff

From Our Partners